Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
Thomas Powles(St Bartholomew's Hospital), Alain Ravaud(Bordeaux Population Health), Sanjeev Mariathasan, Marjorie C. Green, Daniel Castellano(Universidad Complutense de Madrid), Yohann Loriot(Université Paris-Sud), Michiel S. van der Heijden(The Netherlands Cancer Institute), Syed A. Hussain(University Hospitals Plymouth NHS Trust), Na Cui, Ignacio Durán(Instituto de Biomedicina de Sevilla), Toshimi Takano(The Cancer Institute Hospital), Ning Leng, Aristotelis Bamias(Alexandra Hospital), Romain Banchereau, Nicholas J. Vogelzang(Comprehensive Cancer Centers of Nevada), Stéphane Oudard(Délégation Paris 5), Gwénaëlle Gravis(Institut Paoli-Calmettes), Christina Louise Derleth, Ugo De Giorgi(Istituti di Ricovero e Cura a Carattere Scientifico), Edward E. Kadel, Xiaodong Shen, Aude Fléchon(Centre Léon Bérard), Priti S. Hegde, Margitta Retz(Klinikum rechts der Isar)
Cited by 1,413
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
|Journal of Clinical Oncology|2003|3.1k